Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGLRA1GLRB
The experimentally established mechanism targets of Methoxyflurane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8680849 | 0.81 | — | — | |
| SCHEMBL661236 | 0.81 | HTT (0.33) | — | |
| Methoxyflurane SCHEMBL121229 | 0.76 | — | — | |
| Ether SCHEMBL8674343 | 0.74 | — | — | |
| Methoxyflurane SCHEMBL27525605 | 0.73 | — | — | |
| SCHEMBL5704649 | 0.72 | MEN1 (0.35) | — | |
| SCHEMBL29222 | 0.68 | — | — | |
| SCHEMBL4867929 | 0.68 | — | — | |
| SCHEMBL19409473 | 0.68 | — | — | |
| SCHEMBL12924064 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0861268-A1 | INHIBITORY AND NON-INHIBITORY ANTIGEN BINDING POLYPEPTIDES AGAINST HUMAN P450 ENZYMES | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997019112-A1 | INHIBITORY AND NON-INHIBITORY ANTIGEN BINDING POLYPEPTIDES AGAINST HUMAN P450 ENZYMES | UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-05-29 | — | — | WO | disclosed |